ViroCell Partners with UCL to Advance Childhood Cancer Research; Bristol Myers Squibb Announces Promising Results in Lymphoma and Myeloma Studies

The partnership leverages ViroCell's expertise in lentiviral vector manufacturing for innovative CAR T-cell therapy. Meanwhile, Bristol Myers Squibb's studies demonstrate potential of CELMoD™ agent golcadomide in non-Hodgkin lymphomas and progress in multiple myeloma research.

• ViroCell Biologics has signed a manufacturing services agreement with University College London (UCL) to accelerate research into the prevention of relapse in childhood blood cancer. The partnership will leverage ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia.
• Bristol Myers Squibb has announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas. The studies demonstrated activity and combinability with rituximab in heavily pretreated patients with diffuse large B-cell lymphoma.
• Bristol Myers Squibb also announced updated results from three key programs within its broad multiple myeloma research pipeline. The data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.

7 Articles

Financial Post Financial Post Financial Post Financial Post Financial Post Financial Post Financial Post